| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/30/2023 | -7.19% | Morgan Stanley | $160 → $8 | Maintains | Underweight |
| 08/14/2023 | 85.61% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 06/30/2023 | 886.08% | Nephron Research | → $85 | Upgrades | Hold → Buy |
| 06/15/2023 | -7.19% | Barclays | $4 → $8 | Downgrades | Overweight → Underweight |
| 05/30/2023 | 50.81% | RBC Capital | $80 → $13 | Maintains | Sector Perform |
| 05/23/2023 | 1756.15% | Morgan Stanley | $12800 → $160 | Maintains | Underweight |
| 05/22/2023 | 148391.88% | Morgan Stanley | $160 → $12800 | Maintains | Underweight |
| 05/19/2023 | 1756.15% | Morgan Stanley | $2 → $160 | Maintains | Underweight |
| 12/13/2022 | -94.2% | Goldman Sachs | → $0.5 | Downgrades | Neutral → Sell |
| 11/16/2022 | -86.08% | Citigroup | $2.25 → $1.2 | Maintains | Neutral |
| 10/11/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/11/2022 | -65.2% | Piper Sandler | $5 → $3 | Maintains | Overweight |
| 05/12/2022 | -65.2% | Goldman Sachs | $3.5 → $3 | Maintains | Neutral |
| 03/29/2022 | -76.8% | JP Morgan | → $2 | Downgrades | Overweight → Neutral |
| 03/04/2022 | -65.2% | RBC Capital | $9 → $3 | Downgrades | Outperform → Sector Perform |
| 03/03/2022 | -76.8% | Morgan Stanley | $4 → $2 | Maintains | Underweight |
| 03/03/2022 | -59.4% | Goldman Sachs | $5 → $3.5 | Maintains | Neutral |
| 03/03/2022 | -53.6% | Barclays | $5.5 → $4 | Maintains | Overweight |
| 03/03/2022 | -42% | Piper Sandler | $10 → $5 | Maintains | Overweight |
| 01/07/2022 | -36.19% | Barclays | $9 → $5.5 | Maintains | Overweight |
| 12/17/2021 | -53.6% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/16/2021 | -53.6% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/14/2021 | -42% | Goldman Sachs | → $5 | Initiates Coverage On | → Neutral |
| 12/10/2021 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 11/12/2021 | -42% | Morgan Stanley | $13 → $5 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | 39.21% | Barclays | $17 → $12 | Maintains | Overweight |
| 11/02/2021 | 4.41% | Cowen & Co. | $14 → $9 | Downgrades | Outperform → Market Perform |
| 09/10/2021 | 62.41% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/31/2021 | 50.81% | Morgan Stanley | $12 → $13 | Maintains | Overweight |
| 08/05/2021 | 39.21% | Morgan Stanley | $18 → $12 | Upgrades | Equal-Weight → Overweight |
| 08/04/2021 | 39.21% | Citigroup | $16 → $12 | Upgrades | Neutral → Buy |
| 07/19/2021 | 108.82% | Morgan Stanley | → $18 | Initiates Coverage On | → Equal-Weight |
| 07/19/2021 | 120.42% | JP Morgan | → $19 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 74.01% | Wolfe Research | → $15 | Initiates Coverage On | → Peer Perform |
| 07/19/2021 | 317.63% | Goldman Sachs | → $36 | Initiates Coverage On | → Buy |
| 07/19/2021 | 155.22% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 85.61% | Citigroup | → $16 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 178.42% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
What is the target price for Bright Health Gr (BHG)?
The latest price target for Bright Health Gr (NYSE: BHG) was reported by Morgan Stanley on August 30, 2023. The analyst firm set a price target for $8.00 expecting BHG to fall to within 12 months (a possible -7.19% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bright Health Gr (BHG)?
The latest analyst rating for Bright Health Gr (NYSE: BHG) was provided by Morgan Stanley, and Bright Health Gr maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Bright Health Gr (BHG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bright Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bright Health Gr was filed on August 30, 2023 so you should expect the next rating to be made available sometime around August 30, 2024.
Is the Analyst Rating Bright Health Gr (BHG) correct?
While ratings are subjective and will change, the latest Bright Health Gr (BHG) rating was a maintained with a price target of $160.00 to $8.00. The current price Bright Health Gr (BHG) is trading at is $8.62, which is out of the analyst's predicted range.